SLXN - Silexion Growth-Adjusted Payback Ratio

Symbol and logo of brand Silexion Therapeutics Corp (SLXN)

Silexion Therapeutics Corp (SLXN) is mitigating scientific risks by developing KRAS mutation therapies to combat various solid tumors. Business growth is driven by partnerships with RNA-drug laboratories and the acquisition of patents. However, capital shortages and the risk of clinical trial failure are weighing on the stock price. The P/E-to-growth trend reflects the market consensus, where the metric value stands at 0.00.

SLXN Silexion Price/Earnings to Growth Ratio (08/17/2024 - 11/18/2026)

Metric breakdowns and analytics for Silexion Therapeutics Corp (SLXN)

- current price and projected stock value:
Fundamental company analysis:Silexion Therapeutics Corp SLXN
Original product of Silexion

The PEG ratio relates the market value of earnings to their growth rate, allowing for the identification of fundamental asset undervaluation when values fall below one. For Silexion Therapeutics Corp (SLXN), which minimizes capital expenditures by outsourcing RNA therapy development, the growth-adjusted P/E helps filter out volatility by assessing the efficiency of its asset-light operating model within the context of long-term capitalization potential.